What Happened

Mineralys Therapeutics presented late-breaking data at ENDO 2026 on lorundrostat’s effects on heart failure (HF) risk biomarkers in uncontrolled hypertension. The post hoc proteomic analysis of 1,004 participants from the Launch-HTN and Advance-HTN trials showed significant changes in RAAS-related and HF risk biomarkers.

Who Is Affected

This development primarily affects patients with uncontrolled hypertension and comorbid conditions such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA). Healthcare providers and biotech investors are also key stakeholders.

Market Impact

• Lorundrostat’s potential to reduce HF risk biomarkers could position it as a leading treatment for uncontrolled hypertension.
• The FDA PDUFA target date of December 22, 2026, sets a critical milestone for market entry.
• Mineralys Therapeutics’ recent financing and royalty transactions indicate significant capital moves alongside scientific updates.

What to Watch

Watch for the FDA’s decision on lorundrostat by December 22, 2026, and further clinical trial outcomes. Monitor Mineralys Therapeutics’ balance sheet moves and their impact on the company’s risk profile.